Tenax Therapeutics Inc (TENX)
3.549
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
3.66
+0.11
(+3.13%)
After-Hours: 20:00
Tenax Therapeutics Net Income (Quarterly): -3.226M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -3.226M |
| September 30, 2023 | -1.972M |
| June 30, 2023 | -1.106M |
| March 31, 2023 | -1.407M |
| December 31, 2022 | -2.549M |
| September 30, 2022 | -2.916M |
| June 30, 2022 | -2.861M |
| March 31, 2022 | -2.722M |
| December 31, 2021 | -3.211M |
| September 30, 2021 | -3.799M |
| June 30, 2021 | -1.717M |
| March 31, 2021 | -23.75M |
| December 31, 2020 | -2.830M |
| September 30, 2020 | -2.220M |
| June 30, 2020 | -2.146M |
| March 31, 2020 | -2.655M |
| December 31, 2019 | -2.792M |
| September 30, 2019 | -2.224M |
| June 30, 2019 | -1.762M |
| March 31, 2019 | -1.617M |
| December 31, 2018 | -2.217M |
| September 30, 2018 | -1.536M |
| June 30, 2018 | -1.868M |
| March 31, 2018 | -1.193M |
| December 31, 2017 | -1.344M |
| Date | Value |
|---|---|
| September 30, 2017 | -1.234M |
| June 30, 2017 | -2.986M |
| March 31, 2017 | -3.276M |
| December 31, 2016 | -29.65M |
| September 30, 2016 | -4.274M |
| June 30, 2016 | -4.641M |
| March 31, 2016 | -5.362M |
| October 31, 2015 | -3.524M |
| September 30, 2015 | -2.920M |
| July 31, 2015 | -3.034M |
| April 30, 2015 | -4.987M |
| March 31, 2015 | -2.939M |
| January 31, 2015 | -2.868M |
| October 31, 2014 | -4.055M |
| July 31, 2014 | -2.171M |
| April 30, 2014 | -10.41M |
| January 31, 2014 | -3.351M |
| October 31, 2013 | -3.532M |
| July 31, 2013 | -2.245M |
| April 30, 2013 | -1.859M |
| January 31, 2013 | -2.413M |
| October 31, 2012 | -1.557M |
| July 31, 2012 | -3.586M |
| April 30, 2012 | -2.615M |
| January 31, 2012 | -7.299M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-23.75M
Minimum
Mar 2021
-1.106M
Maximum
Jun 2023
-3.572M
Average
-2.655M
Median
Mar 2020
Net Income (Quarterly) Benchmarks
| CEL-SCI Corp | -7.245M |
| AIM ImmunoTech Inc | -12.58M |
| IGC Pharma Inc | -5.589M |
| NovaBay Pharmaceuticals Inc | -3.214M |
| Protalix BioTherapeutics Inc | -4.595M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.341M |
| EPS Diluted (Quarterly) | -11.84 |
| Enterprise Value | -2.342M |
| Earnings Yield | -964.8% |